Expert Interview
A look at Arrowhead Pharmaceuticals’ and Wave LifeSciences interim clinical data for their RNA-based obesity programs, including ARO-INHBE / ARO-ALK7 and WVE-007
Ticker(s): ARWR, WVEInstitution: Harvard Medical School
- Medical Director, Obesity Clinic Program and Inpatient Diabetes Program & Associate Professor at Harvard Medical School.
- Manages ~1,000 patients with diabetes and obesity
- Research interests include diabetes and obesity, metabolic syndrome and obesity and cardiovascular disease with a focus on understanding metabolic and cardiovascular benefits of lifestyle changes and weight loss.
What stands out most to you in the interim Phase 1/2a data from Arrowhead Pharmaceuticals, particularly regarding visceral fat reduction and body composition changes in obese patients with type 2 diabetes?
Added By: sara_adminHow clinically meaningful do you find the added weight loss and fat reduction seen with ARO-INHBE in combination with tirzepatide compared with tirzepatide alone in this harder-to-treat diabetic population?
Added By: sara_adminGiven the monotherapy data, how do you view the potential role of targeting the Activin E/ALK7 pathway directly, including the early results seen with ARO-ALK7, relative to incretin-based approaches?
Added By: sara_adminHow do you differentiate WVE-007 from ARO-INHBE / ARO-ALK7?
Added By: ben_adminRank your level of excitement for WVE-007 and ARO-INHBE / ARO-ALK7 on a scale of 1-10
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
